Belite Bio, Inc

Stage 3 · Topping · week 1⚠ 2→3 today

As of Oct 22, 2026, Belite Bio is in Stage 3, the topping phase, now in its first week (since Oct 22, 2026). It closed at $150.27, 22.4% below its 52-week high and below its 200-day average, which is rising.

$150.27

-1.90% today

$6.1B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is BLTE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 27w

S2 33w

S2 34w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 1w → S1 5w → S2 27w → S3 10w → S2 33w → S3 9w → S2 11w → S3 4w → S4 1w → S1 7w → S2 34w → S3 13w → S4 2w → S1 4w → S2 7w → S3 1w current

Total tracked: 165 weeks across 16 stage runs.

BLTE among Biotechnology77th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…77	BLTEBelite Bio, Inc	Stage 3 · wk 1	90	−10.9%

vs 52W High

-22.4%

$89.36 lo$193.61 hi

22.4% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-6.5%

200 DMA: $160.67 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.66x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.9%

-2.0%

-8.6%

YTD

-5.7%

+63.3%

Scan Membership

Breakout Watch

Latest: 2025-03-24

4 appearances in last 60 days. First seen: 2023-02-14.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S32→3

Wk 1 · Vol 0.66x

2026-10-21S2

Wk 7 · Vol 0.52x

2026-10-20S2

Wk 7 · Vol 1.10x

2026-10-19S2

Wk 7 · Vol 0.86x

2026-10-16S2

Wk 6 · Vol 1.03x

2026-10-15S2

Wk 6 · Vol 1.04x

2026-10-14S2

Wk 6 · Vol 0.85x

2026-10-13S2

Wk 6 · Vol 1.25x

2026-10-12S2

Wk 6 · Vol 1.41x

2026-10-09S2

Wk 5 · Vol 0.97x

2026-10-08S2

Wk 5 · Vol 0.83x

2026-10-07S2

Wk 5 · Vol 0.52x

Moving averages & range

50 DMA

$163.38

200 DMA

$160.67

52W High

$193.61

52W Low

$89.36

5D Low

$142.78

Resistance levels (recent highs)

20d High

$169.82

60d High

$193.61

120d High

$193.61

250d High

$193.61

Next resistance

+13.0%

to 20d High

ROE

-22.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 7.8

Belite Bio: quick answers

What stage is Belite Bio in?

As of Oct 22, 2026, Belite Bio (BLTE) is in Stage 3, the topping phase. It entered Stage 3 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Belite Bio in an uptrend?

Its uptrend has stalled. Belite Bio is in Stage 3, the topping phase that follows an advance. It trades 6.5% below its 200-day average, which is rising.

How far is Belite Bio from its 52-week high?

Belite Bio closed at $150.27 on Oct 22, 2026, 22.4% below its 52-week high of $193.61. Its 52-week low is $89.36.

How has Belite Bio performed over the past year?

As of Oct 22, 2026, Belite Bio is up 63.3% over the past year and down 5.7% so far in 2026.

Which sector and industry is Belite Bio in?

Belite Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.